Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Stevanato Group S.p.A.NYSE: STVN

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 28.7%

Gross margin was 28.7% in Q2 FY2026, up 0.7 pp from a year earlier. On a trailing-twelve-month basis it was 29.2%, up 1.1 pp year over year. Over 3 fiscal years it narrowed by 3.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
28.7%+1.3 pp QoQ
Last fiscal yearDec 2025
29.0%+1.6 pp YoY
LTMJun 2026
29.2%+1.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.7 pp——
1 year+1.6 pp——
3 years-3.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.0%
Year-over-year change
+1.6pp

Gross Margin vs competitors

How STVN compares with its peers on the latest reported figures

  • STVN's LTM Jun 2026 gross margin of 29.2% is the 8th highest of the 10 companies compared; the peer median is 49.4%.
  • Its year-over-year change of +1.1 pp is the 3rd highest of 10, against a peer median of +0.2 pp.
  • Over three fiscal years its change of -3.5 pp compares with a peer median of -2.0 pp.
STVN Competitors Peer median
Gross Margin for STVN and competitors
Company Period LTM level YoY 3-year change
AXSMAxsome Therapeutics, Inc.LTM Jun 202693.2% +1.8 pp+3.0 pp
MASIMasimo CorporationLTM Apr 202661.7% +9.6 pp+9.9 pp
BLCOBausch + Lomb CorporationLTM Jun 202657.2% +0.3 pp-4.9 pp
TFXTeleflex IncorporatedLTM Jun 202653.8% -1.8 pp+1.4 pp
MMSIMerit Medical Systems, Inc.LTM Sep 202649.4% +0.9 pp+3.6 pp
AVTRAvantor, Inc.LTM Jun 202631.8% -1.4 pp-2.0 pp
CHEChemed CorporationLTM Jun 202630.4% -3.2 pp-5.9 pp
STVNStevanato Group S.p.A.LTM Jun 202629.2% +1.1 pp-3.5 pp
ATRAptarGroup, Inc.LTM Jun 202628.3% -6.3 pp-5.4 pp
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 202612.5% +0.2 pp-5.8 pp
NUVLNuvalent, Inc.FY2025— ——
Peer median (excluding STVN) 49.4%+0.2 pp-2.0 pp

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue843.92M983.68M1.09B1.1B1.14B
Cost of Revenue578.52M663.88M745.46M801.72M809.15M
Gross Profit265.41M319.8M339.89M302.32M330.33M
Gross Margin31.4%32.5%31.3%27.4%29.0%
Research & Development29.62M34.39M35.67M31.67M24.4M
Selling, General & Admin82.95M111.83M113.92M118.6M122.85M
Operating Expenses103.18M127.37M139.17M141.18M147.25M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
EBITDA226.93M256.4M272.35M247.8M292.01M
EBITDA Margin26.9%26.1%25.1%22.4%25.6%
Operating Income162.23M192.43M200.72M161.14M183.08M
Operating Margin19.2%19.6%18.5%14.6%16.1%
Interest Income548K648K792K1.72M12.49M
Interest Expense4.87M3.94M4.32M6.86M21.8M
Other Income / Expenses3.45M(4.79M)(11.17M)(854K)(1.44M)
Income Before Tax165.67M187.64M189.55M160.29M181.64M
Pre-Tax Margin19.6%19.1%17.5%14.5%15.9%
Income Tax Expense31.4M44.63M43.86M42.52M47.35M
Net Income134.32M142.85M145.63M117.78M134.28M
Net Margin15.9%14.5%13.4%10.7%11.8%
EPS (Basic)0.530.530.550.430.49
EPS (Diluted)0.530.530.550.430.49
Weighted Avg Shares264.7M264.7M264.95M272.87M273M
Weighted Avg Shares (Diluted)264.7M264.7M264.98M272.88M273M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.